October 14, 2021
Article
While receiving a booster of one’s original COVID-19 shot leads to an immune boost, this was heightened among individuals who received a different booster than their primary vaccine.
October 13, 2021
The FDA suggested that Johnson & Johnson had not conducted an appropriately thorough test to prove its vaccine requires a six-month booster.
New clinical trial is first to describe concomitant administration of any vaccine with either an adenoviral vector or mRNA COVID-19 vaccine.
October 12, 2021
October 11, 2021
No ICU admissions or deaths were reported among Native American patients treated with monoclonal antibodies for COVID-19 in a recent study.
The filing is for the first oral antiviral therapy, and is based off its phase 3 trial.
October 07, 2021
The companies made the request after their recent submission of data to support the emergency use authorization (EUA) in this patient population.
October 05, 2021
AstraZeneca’s long-acting antibody, AZD7442, would act as a supplement to vaccination and could provide up to a year of protection against symptomatic COVID-19.
US federal health agencies are recommending an additional shot for this diverse patient population, and here on some insights about vaccine efficacy and breakthrough infections in these groups.
This study confirmed reports from the CDC and Israel Ministry of Health that found the Pfizer-BioNTech vaccine waned after 6 months.
